Cartesian Therapeutics (RNAC)
Cartesian Therapeutics on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
1.9M
Short interest
settlement 2026-10-15
11.7
Days to cover
-0.9 days vs prior
55.9%
Short share of volume
2026-11-03
1,732
Fails to deliver
settlement 2026-10-08
Thu 5 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-11-03.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in RNAC is 1,875,103 shares, up 71,821 shares over the last month. Over the last 48 readings it ranged from 1,796,563 shares (13 December 2024) to 2,627,712 shares (13 June 2025). The latest reading sits at the bottom of that range. At the reported average volume of 160K shares a day that is 11.7 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/rnac" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 1,875,103 | +1.1% | 159,823 | 11.73 |
| 2026-09-30 | 1,855,626 | +2.9% | 146,843 | 12.64 |
| 2026-09-15 | 1,803,282 | -0.5% | 106,105 | 17.00 |
| 2026-08-31 | 1,811,559 | -3.0% | 135,439 | 13.38 |
| 2026-08-14 | 1,868,036 | +1.3% | 104,625 | 17.85 |
| 2026-07-31 | 1,843,723 | -4.3% | 123,813 | 14.89 |
| 2026-07-15 | 1,925,634 | +2.1% | 156,524 | 12.30 |
| 2026-06-30 | 1,886,695 | -2.1% | 384,612 | 4.91 |
| 2026-06-15 | 1,927,010 | -15.9% | 594,373 | 3.24 |
| 2026-05-29 | 2,291,824 | +3.4% | 185,315 | 12.37 |
| 2026-05-15 | 2,216,090 | +2.2% | 186,619 | 11.87 |
| 2026-04-30 | 2,169,081 | -2.0% | 169,608 | 12.79 |
| 2026-04-15 | 2,214,144 | +2.0% | 158,025 | 14.01 |
| 2026-03-31 | 2,170,494 | +2.4% | 148,078 | 14.66 |
| 2026-03-13 | 2,119,136 | -1.4% | 444,451 | 4.77 |
| 2026-02-27 | 2,148,586 | -3.0% | 137,501 | 15.63 |
| 2026-02-13 | 2,215,393 | +2.5% | 99,786 | 22.20 |
| 2026-01-30 | 2,161,341 | +1.5% | 86,573 | 24.97 |
| 2026-01-15 | 2,128,743 | -8.9% | 156,281 | 13.62 |
| 2025-12-31 | 2,337,271 | -0.3% | 226,008 | 10.34 |
| 2025-12-15 | 2,343,662 | +12.6% | 276,910 | 8.46 |
| 2025-11-28 | 2,080,754 | +2.5% | 109,471 | 19.01 |
| 2025-11-14 | 2,029,938 | -4.6% | 109,511 | 18.54 |
| 2025-10-31 | 2,128,562 | +0.2% | 295,365 | 7.21 |
| 2025-10-15 | 2,124,297 | -5.4% | 70,403 | 30.17 |
| 2025-09-30 | 2,244,672 | -3.7% | 96,012 | 23.38 |
| 2025-09-15 | 2,331,102 | -1.4% | 52,354 | 44.53 |
| 2025-08-29 | 2,364,831 | -0.1% | 52,056 | 45.43 |
| 2025-08-15 | 2,367,515 | -3.1% | 46,316 | 51.12 |
| 2025-07-31 | 2,442,330 | -6.0% | 61,536 | 39.69 |
| 2025-07-15 | 2,599,153 | +1.5% | 82,757 | 31.41 |
| 2025-06-30 | 2,561,225 | -2.5% | 78,874 | 32.47 |
| 2025-06-13 | 2,627,712 | +3.0% | 65,664 | 40.02 |
| 2025-05-30 | 2,551,444 | +1.8% | 62,274 | 40.97 |
| 2025-05-15 | 2,506,042 | -1.1% | 87,262 | 28.72 |
| 2025-04-30 | 2,534,226 | +6.3% | 69,138 | 36.65 |
| 2025-04-15 | 2,383,018 | +13.6% | 162,762 | 14.64 |
| 2025-03-31 | 2,097,191 | +3.3% | 103,188 | 20.32 |
| 2025-03-14 | 2,030,051 | -3.4% | 89,343 | 22.72 |
| 2025-02-28 | 2,101,196 | +3.9% | 69,762 | 30.12 |
| 2025-02-14 | 2,022,042 | +2.6% | 52,131 | 38.79 |
| 2025-01-31 | 1,969,856 | -1.9% | 70,021 | 28.13 |
| 2025-01-15 | 2,008,843 | +0.1% | 110,341 | 18.21 |
| 2024-12-31 | 2,006,013 | +11.7% | 162,687 | 12.33 |
| 2024-12-13 | 1,796,563 | -1.9% | 144,967 | 12.39 |
| 2024-11-29 | 1,830,389 | -1.6% | 96,571 | 18.95 |
| 2024-11-15 | 1,859,311 | -3.6% | 132,838 | 14.00 |
| 2024-10-31 | 1,928,027 | -0.9% | 68,723 | 28.06 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 3 November 2026, the short share of RNAC volume is 55.9%, up 14.3 points over the last five sessions. Over the last 30 readings it ranged from 41.7% (27 October 2026) to 77.4% (1 October 2026). The latest reading is 5.1 points below the 30-session average of 61.0%, on 26K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-03 | 15K | 26K | 55.9% | 0 |
| 2026-11-02 | 31K | 46K | 67.3% | 0 |
| 2026-10-30 | 16K | 22K | 72.7% | 0 |
| 2026-10-29 | 23K | 43K | 54.3% | 0 |
| 2026-10-28 | 18K | 38K | 48.3% | 0 |
| 2026-10-27 | 23K | 55K | 41.7% | 0 |
| 2026-10-26 | 38K | 53K | 71.6% | 0 |
| 2026-10-23 | 21K | 41K | 51.3% | 250 |
| 2026-10-22 | 28K | 38K | 74.1% | 0 |
| 2026-10-21 | 21K | 37K | 57.5% | 0 |
| 2026-10-20 | 40K | 77K | 51.7% | 99 |
| 2026-10-19 | 49K | 68K | 71.0% | 0 |
| 2026-10-16 | 19K | 37K | 53.2% | 67 |
| 2026-10-15 | 24K | 37K | 65.4% | 0 |
| 2026-10-14 | 39K | 51K | 77.1% | 22 |
| 2026-10-13 | 19K | 39K | 47.3% | 0 |
| 2026-10-12 | 27K | 51K | 52.4% | 100 |
| 2026-10-09 | 23K | 45K | 49.7% | 0 |
| 2026-10-08 | 32K | 50K | 64.1% | 0 |
| 2026-10-07 | 21K | 31K | 66.3% | 0 |
| 2026-10-06 | 60K | 82K | 73.9% | 0 |
| 2026-10-05 | 35K | 65K | 54.2% | 0 |
| 2026-10-02 | 28K | 57K | 49.5% | 0 |
| 2026-10-01 | 47K | 61K | 77.4% | 0 |
| 2026-09-30 | 51K | 80K | 64.3% | 0 |
| 2026-09-29 | 39K | 66K | 59.4% | 0 |
| 2026-09-28 | 41K | 60K | 68.4% | 100 |
| 2026-09-25 | 36K | 60K | 60.6% | 0 |
| 2026-09-24 | 43K | 77K | 56.2% | 0 |
| 2026-09-23 | 29K | 39K | 74.4% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 8 October 2026, the fails-to-deliver balance in RNAC is 1,732 shares, up 443 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (21 April 2026) to 27,960 shares (20 May 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-08 | 1,732 | $6.68 | $12K |
| 2026-10-05 | 1,289 | $7.36 | $9K |
| 2026-09-28 | 476 | $7.41 | $4K |
| 2026-09-21 | 60 | $8.03 | $482 |
| 2026-09-17 | 1,135 | $7.91 | $9K |
| 2026-09-14 | 5,411 | $8.19 | $44K |
| 2026-09-03 | 1,271 | $9.08 | $12K |
| 2026-08-19 | 936 | $9.20 | $9K |
| 2026-08-12 | 198 | $8.59 | $2K |
| 2026-08-07 | 975 | $8.76 | $9K |
| 2026-07-27 | 706 | $7.88 | $6K |
| 2026-07-23 | 3 | $8.13 | $24 |
| 2026-07-13 | 2 | $9.46 | $19 |
| 2026-06-26 | 432 | $8.93 | $4K |
| 2026-06-18 | 5,862 | $9.88 | $58K |
| 2026-06-17 | 54 | $9.05 | $489 |
| 2026-06-10 | 3,150 | $6.85 | $22K |
| 2026-05-27 | 3,708 | $6.45 | $24K |
| 2026-05-26 | 3,867 | $6.75 | $26K |
| 2026-05-20 | 27,960 | $6.09 | $170K |
| 2026-05-12 | 17,531 | $8.53 | $150K |
| 2026-05-04 | 2,193 | $6.22 | $14K |
| 2026-04-21 | 1 | $6.94 | $7 |
| 2026-04-15 | 5,384 | $6.35 | $34K |
| 2026-04-07 | 2,347 | $6.24 | $15K |
| 2026-04-06 | 150 | $6.26 | $939 |
| 2026-04-02 | 3,602 | $6.39 | $23K |
| 2026-03-31 | 72 | $5.88 | $423 |
| 2026-03-12 | 300 | $8.26 | $2K |
| 2026-03-11 | 6,040 | $8.55 | $52K |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for RNAC in the last 90 days. The most recent filings are listed below. Latest filing: Kalayoglu Murat (TenPercentOwner) on 2026-04-02.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-04-02 | Kalayoglu Murat | TenPercentOwner | Exercise or conversion | 758K | price not stated in the filing | not stated | 5.3M |
| 2026-04-02 | Hoge Elizabeth | TenPercentOwner | Exercise or conversion | 758K | price not stated in the filing | not stated | 5.3M |
| 2026-03-13 | Singer Michael | Director | Gift | 7K | $0.00 | $0 | 50K |
| 2026-01-06 | Miljkovic Milos | Chief Medical Officer | Sell | 4K | $6.82 | $24K | 59K |
| 2026-01-06 | Davis Blaine | Chief Financial Officer | Sell | 11K | $6.82 | $72K | 121K |
| 2026-01-06 | Brunn Carsten | President and CEO | Sell | 24K | $6.82 | $162K | 324K |
| 2026-01-02 | DeSilva Nishan M | Director | Grant | 3K | $0.00 | $0 | 11K |
| 2026-01-02 | Malik Kemal | Director | Grant | 3K | $0.00 | $0 | 11K |
| 2026-01-02 | Miljkovic Milos | Chief Medical Officer | Grant | 27K | $0.00 | $0 | 62K |
| 2026-01-02 | ZENNER PATRICK J | Director | Grant | 3K | $0.00 | $0 | 13K |
| 2026-01-02 | Seymour June Ann | Chief Accounting Officer | Grant | 7K | $0.00 | $0 | 7K |
| 2026-01-02 | Davis Blaine | Chief Financial Officer | Grant | 37K | $0.00 | $0 | 132K |
| 2026-01-02 | English Emily | Chief Operations Officer | Grant | 24K | $0.00 | $0 | 94K |
| 2026-01-02 | Singer Michael | Director | Grant | 3K | $0.00 | $0 | 56K |
| 2026-01-02 | SPRINGER TIMOTHY A | Director, 10% owner | Grant | 3K | $0.00 | $0 | 8.6M |
| 2026-01-02 | Kalayoglu Murat | Director, 10% owner | Grant | 3K | $0.00 | $0 | 512K |
| 2026-01-02 | Brunn Carsten | President and CEO | Grant | 143K | $0.00 | $0 | 347K |
| 2026-01-02 | BARABE TIMOTHY C | Director | Grant | 3K | $0.00 | $0 | 57K |
| 2025-12-30 | English Emily | Chief Operations Officer | Exercise or conversion | 8K | $3.30 | $25K | 70K |
| 2025-12-16 | Bot Adrian Ion | Director | Grant | 6K | $0.00 | $0 | 6K |
| 2025-12-04 | BARABE TIMOTHY C | Director | Buy | 30K | $6.86 | $206K | 54K |
| 2025-11-28 | English Emily | Chief Operations Officer | Exercise or conversion | 8K | $3.30 | $25K | 63K |
| 2025-11-18 | Singer Michael | Director | Gift | 20K | $0.00 | $0 | 54K |
| 2025-05-12 | English Emily | Chief Operations Officer | Exercise or conversion | 8K | $3.30 | $25K | 55K |
| 2025-04-15 | English Emily | Chief Operations Officer | Exercise or conversion | 8K | $3.30 | $25K | 48K |
| 2025-04-11 | SPRINGER TIMOTHY A | Director,TenPercentOwner | Buy | 36K | $10.77 | $391K | 657K |
| 2025-04-11 | SPRINGER TIMOTHY A | Director,TenPercentOwner | Buy | 6K | $10.77 | $69K | 8.6M |
| 2025-04-10 | SPRINGER TIMOTHY A | Director,TenPercentOwner | Buy | 3K | $10.92 | $38K | 620K |
| 2025-04-10 | SPRINGER TIMOTHY A | Director,TenPercentOwner | Buy | 609 | $10.92 | $7K | 8.6M |
| 2025-04-10 | SPRINGER TIMOTHY A | Director,TenPercentOwner | Buy | 8K | $10.43 | $83K | 8.6M |
| 2025-04-10 | SPRINGER TIMOTHY A | Director,TenPercentOwner | Buy | 45K | $10.43 | $471K | 617K |
| 2025-04-09 | SPRINGER TIMOTHY A | Director,TenPercentOwner | Buy | 7K | $9.43 | $69K | 8.6M |
| 2025-04-09 | SPRINGER TIMOTHY A | Director,TenPercentOwner | Buy | 42K | $9.43 | $392K | 571K |
| 2025-04-09 | SPRINGER TIMOTHY A | Director,TenPercentOwner | Buy | 178 | $9.95 | $2K | 572K |
| 2025-04-09 | SPRINGER TIMOTHY A | Director,TenPercentOwner | Buy | 31 | $9.95 | $308 | 8.6M |
| 2025-03-20 | SPRINGER TIMOTHY A | Director,TenPercentOwner | Buy | 55K | $15.59 | $856K | 8.6M |
| 2025-03-19 | SPRINGER TIMOTHY A | Director,TenPercentOwner | Buy | 20K | $14.97 | $303K | 8.6M |
| 2025-03-18 | SPRINGER TIMOTHY A | Director,TenPercentOwner | Buy | 15K | $14.42 | $213K | 8.5M |
| 2025-01-14 | SPRINGER TIMOTHY A | Director,TenPercentOwner | Buy | 4K | $18.00 | $72K | 8.5M |
| 2025-01-13 | SPRINGER TIMOTHY A | Director,TenPercentOwner | Buy | 9K | $17.78 | $160K | 8.5M |
| 2025-01-13 | SPRINGER TIMOTHY A | Director,TenPercentOwner | Buy | 8K | $16.86 | $134K | 8.5M |
| 2025-01-10 | Jewell Christopher M | Chief Scientific Officer | Exercise or conversion | 9K | $3.23 | $29K | 62K |
| 2025-01-06 | Davis Blaine | Chief Financial Officer | Sell | 4K | $16.83 | $68K | 95K |
| 2025-01-06 | Brunn Carsten | President and CEO | Sell | 9K | $16.83 | $147K | 204K |
| 2025-01-06 | English Emily | Chief Operations Officer | Sell | 906 | $16.83 | $15K | 40K |
| 2025-01-06 | Jewell Christopher M | Chief Scientific Officer | Sell | 1K | $16.83 | $22K | 53K |
| 2025-01-06 | Miljkovic Milos | Chief Medical Officer | Sell | 948 | $16.83 | $16K | 35K |
| 2025-01-06 | Kurtoglu Metin | Chief Technology Officer | Sell | 2K | $16.83 | $41K | 62K |
| 2025-01-03 | Davis Blaine | Chief Financial Officer | Sell | 4K | $16.72 | $66K | 99K |
| 2025-01-03 | Brunn Carsten | President and CEO | Sell | 9K | $16.72 | $143K | 213K |
| 2025-01-03 | English Emily | Chief Operations Officer | Sell | 891 | $16.72 | $15K | 41K |
| 2025-01-03 | Jewell Christopher M | Chief Scientific Officer | Sell | 1K | $16.72 | $21K | 55K |
| 2025-01-03 | Miljkovic Milos | Chief Medical Officer | Sell | 932 | $16.72 | $16K | 36K |
| 2025-01-03 | Kurtoglu Metin | Chief Technology Officer | Sell | 2K | $16.72 | $40K | 65K |
| 2025-01-02 | DeSilva Nishan M | Director | Grant | 3K | $0.00 | $0 | 9K |
| 2025-01-02 | COX CARRIE SMITH | Director | Grant | 3K | $0.00 | $0 | 16K |
| 2025-01-02 | Singer Michael | Director | Grant | 3K | $0.00 | $0 | 74K |
| 2025-01-02 | Kurtoglu Metin | Chief Technology Officer | Grant | 16K | $0.00 | $0 | 67K |
| 2025-01-02 | Malik Kemal | Director | Grant | 3K | $0.00 | $0 | 9K |
| 2025-01-02 | SPRINGER TIMOTHY A | Director,TenPercentOwner | Grant | 3K | $0.00 | $0 | 8.5M |
| 2025-01-02 | BARABE TIMOTHY C | Director | Grant | 3K | $0.00 | $0 | 24K |
| 2025-01-02 | Kalayoglu Murat | Director,TenPercentOwner | Grant | 3K | $0.00 | $0 | 509K |
| 2025-01-02 | Miljkovic Milos | Chief Medical Officer | Grant | 19K | $0.00 | $0 | 37K |
| 2025-01-02 | ZENNER PATRICK J | Director | Grant | 3K | $0.00 | $0 | 10K |
| 2025-01-02 | Davis Blaine | Chief Financial Officer | Grant | 22K | $0.00 | $0 | 103K |
| 2025-01-02 | English Emily | Chief Operations Officer | Grant | 16K | $0.00 | $0 | 42K |
| 2025-01-02 | Jewell Christopher M | Chief Scientific Officer | Grant | 16K | $0.00 | $0 | 56K |
| 2025-01-02 | Brunn Carsten | President and CEO | Grant | 58K | $0.00 | $0 | 221K |
| 2024-12-26 | English Emily | SVP, Head of Manufacturing | Exercise or conversion | 8K | $3.30 | $25K | 26K |
| 2024-12-26 | Singer Michael | Director | Gift | 20K | $0.00 | $0 | 71K |
| 2024-12-23 | SPRINGER TIMOTHY A | Director,TenPercentOwner | Buy | 5K | $19.00 | $98K | 8.5M |
| 2024-12-20 | SPRINGER TIMOTHY A | Director,TenPercentOwner | Buy | 22K | $18.94 | $413K | 8.5M |
| 2024-12-19 | SPRINGER TIMOTHY A | Director,TenPercentOwner | Buy | 11K | $17.39 | $197K | 8.5M |
| 2024-12-19 | SPRINGER TIMOTHY A | Director,TenPercentOwner | Buy | 3K | $18.93 | $64K | 8.5M |
| 2024-12-19 | SPRINGER TIMOTHY A | Director,TenPercentOwner | Buy | 11K | $18.35 | $193K | 8.5M |
| 2024-12-10 | Kurtoglu Metin | Chief Technology Officer | Sell | 3K | $24.35 | $71K | 51K |
| 2024-12-10 | Kurtoglu Metin | Chief Technology Officer | Exercise or conversion | 3K | $1.41 | $4K | 54K |
| 2024-12-09 | Kurtoglu Metin | Chief Technology Officer | Sell | 6K | $25.26 | $157K | 56K |
| 2024-12-09 | Kurtoglu Metin | Chief Technology Officer | Sell | 5K | $25.83 | $117K | 51K |
| 2024-12-09 | Kurtoglu Metin | Chief Technology Officer | Exercise or conversion | 11K | $1.41 | $15K | 62K |
| 2024-11-21 | Kurtoglu Metin | Chief Technology Officer | Exercise or conversion | 33K | $1.41 | $46K | 84K |
| 2024-11-21 | Kurtoglu Metin | Chief Technology Officer | Sell | 33K | $16.67 | $547K | 51K |
| 2024-11-20 | Jewell Christopher M | Chief Scientific Officer | Exercise or conversion | 14K | $3.23 | $45K | 40K |
| 2024-11-20 | Kurtoglu Metin | Chief Technology Officer | Exercise or conversion | 6K | $1.41 | $8K | 57K |
| 2024-11-20 | Kurtoglu Metin | Chief Technology Officer | Sell | 6K | $17.28 | $97K | 51K |
| 2024-11-20 | Kurtoglu Metin | Chief Technology Officer | Sell | 100 | $18.09 | $2K | 51K |
| 2024-11-19 | Singer Michael | Director | Gift | 29K | $0.00 | $0 | 91K |
| 2024-11-19 | Kurtoglu Metin | Chief Technology Officer | Exercise or conversion | 200 | $1.41 | $282 | 51K |
| 2024-11-19 | Kurtoglu Metin | Chief Technology Officer | Sell | 200 | $19.50 | $4K | 51K |
| 2024-11-18 | Kurtoglu Metin | Chief Technology Officer | Sell | 18K | $18.58 | $329K | 51K |
| 2024-11-18 | Kurtoglu Metin | Chief Technology Officer | Sell | 17K | $18.19 | $303K | 69K |
| 2024-11-18 | Kurtoglu Metin | Chief Technology Officer | Exercise or conversion | 34K | $1.41 | $49K | 85K |
| 2024-11-18 | SPRINGER TIMOTHY A | Director,TenPercentOwner | Buy | 20K | $18.42 | $372K | 8.5M |
| 2024-11-18 | SPRINGER TIMOTHY A | Director,TenPercentOwner | Buy | 38K | $17.96 | $685K | 8.4M |
| 2024-11-15 | Jewell Christopher M | Chief Scientific Officer | Exercise or conversion | 16K | $3.23 | $52K | 42K |
| 2024-11-15 | Jewell Christopher M | Chief Scientific Officer | Sell | 16K | $17.06 | $274K | 26K |
| 2024-11-15 | Miljkovic Milos | Chief Medical Officer | Exercise or conversion | 20K | $3.23 | $65K | 38K |
| 2024-11-15 | Miljkovic Milos | Chief Medical Officer | Sell | 20K | $17.14 | $343K | 18K |
| 2024-11-15 | Kurtoglu Metin | Chief Technology Officer | Sell | 22K | $17.20 | $380K | 51K |
| 2024-11-15 | Kurtoglu Metin | Chief Technology Officer | Exercise or conversion | 22K | $1.41 | $31K | 73K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON5 Form 144 notices on file for RNAC worth $532K at the prices reported; 0 in the last 90 days worth $0. Latest: MILOS MILJKOVIC filed on 2026-06-09 to sell 35,038 shares ($233K) from 2026-06-09.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-06-09 | MILOS MILJKOVICFormer Affiliate | 35K | $233K | 0.119% | 2026-06-09 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-02 | MILOS MILJKOVICFormer Affiliate | 4K | $25K | 0.013% | 2026-06-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-13 | CHRISTOPHER M JEWELLFormer Affiliate | 9K | $69K | 0.035% | 2026-01-13 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-09 | CHRISTOPHER M JEWELLFormer Affiliate | 2K | $12K | 0.006% | 2026-01-09 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-19 | CHRISTOPHER M JEWELLFormer Affiliate | 27K | $193K | 0.104% | 2025-11-19 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON10 holders report 5% or more of RNAC in their latest filing, 4 on Schedule 13D (active intent). The largest reported stake is Murat Kalayoglu at 19.9% of the class (5,833,971 shares), filed 2026-04-02 for an event on 2026-03-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-13 | 13G | Barclays PLCparent holding company | 1.8M | 6.0% | 2026-06-30 |
| 2026-07-22 | 13G/Ano. 1 | JPMORGAN CHASE & CO.parent holding company | 1.5M | 4.8% | 2026-06-30 |
| 2026-05-06 | 13G/Ano. 4 | FMR LLCparent holding company | 800K | 3.0% | 2026-03-31 |
| 2026-05-06 | 13G/Ano. 4 | Abigail P. Johnsonindividual | 800K | 3.0% | 2026-03-31 |
| 2026-04-02 | 13D/Ano. 3 | Murat Kalayogluindividual | 5.8M | 19.9% | 2026-03-31 |
| 2026-04-02 | 13D/Ano. 3 | Seven One Eight Three Four Irrevocable Trustother entity | 5.3M | 18.1% | 2026-03-31 |
| 2026-04-02 | 13D/Ano. 3 | Elizabeth Hogeparent holding company, individual | 5.3M | 18.1% | 2026-03-31 |
| 2026-04-02 | 13D/Ano. 3 | Sinan Kalayogluparent holding company, individual | 5.3M | 18.1% | 2026-03-31 |
| 2026-03-13 | 13G | Squarepoint Ops LLCinvestment adviser | 2.2M | 8.3% | 2026-03-09 |
| 2026-03-13 | 13G | Squarepoint Capital LLPinvestment adviser | 2.2M | 8.3% | 2026-03-09 |
| 2026-03-13 | 13G | Squarepoint Operations Private Limitedinvestment adviser | 2.2M | 8.3% | 2026-03-09 |
| 2026-03-13 | 13G | Squarepoint (DIFC) Ltdinvestment adviser | 2.2M | 8.3% | 2026-03-09 |
| 2026-03-13 | 13G | Squarepoint Master Fund Limitedother entity | 2.2M | 8.2% | 2026-03-09 |
| 2026-03-13 | 13G | Squarepoint Core Master Fund Limitedother entity | 31K | 0.1% | 2026-03-09 |
13F holders
Tracked managers holding RNAC at their latest 13F. JSON6 of the 30 tracked managers held RNAC at their latest 13F, $11.0M in total at quarter-end prices. AQR Capital Management is the largest at $3.7M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 5 added shares and 1 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| AQR Capital Management | 2026-06-30 | 356K | $3.7M | 0.00% | +272K |
| Millennium Management | 2026-06-30 | 310K | $3.2M | 0.00% | +26K |
| Two Sigma Investments | 2026-06-30 | 296K | $3.1M | 0.00% | +129K |
| Point72 Asset Management | 2026-06-30 | 44K | $455K | 0.00% | new |
| D. E. Shaw & Co. | 2026-06-30 | 29K | $299K | 0.00% | new |
| Renaissance Technologies | 2026-06-30 | 20K | $212K | 0.00% | -47K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Cartesian Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Cartesian Therapeutics (RNAC), SEC CIK 1453687, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-03.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-08.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-06-09.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-13.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-06.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-04-02.JSON and CSV
- Company record
- EDGAR filing index for CIK 1453687Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
Datasets
Frequently Asked Questions
How much of RNAC is sold short?
1,875,103 shares were held short at the 2026-10-15 settlement, 11.7 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is RNAC's daily short volume?
On 2026-11-03, 14,663 of the 26,219 RNAC shares reported to FINRA were sold short, 55.9% of the day's reported volume. Short volume is a flow for one day, not a position.
Does RNAC have fails to deliver?
The SEC's latest file shows 1,732 RNAC shares failed to deliver at settlement 2026-10-08. Fails are reported per settlement date and published twice a month with a lag.
Are RNAC insiders buying or selling?
No open-market insider trades were reported for RNAC in the last 90 days. The most recent filings are listed below. Latest filing: Kalayoglu Murat (TenPercentOwner) on 2026-04-02.
Have RNAC insiders filed to sell?
5 Form 144 notices on file for RNAC worth $532K at the prices reported; 0 in the last 90 days worth $0. Latest: MILOS MILJKOVIC filed on 2026-06-09 to sell 35,038 shares ($233K) from 2026-06-09.
Who owns 5% or more of RNAC?
10 holders report 5% or more of RNAC in their latest filing, 4 on Schedule 13D (active intent). The largest reported stake is Murat Kalayoglu at 19.9% of the class (5,833,971 shares), filed 2026-04-02 for an event on 2026-03-31.
Which tracked 13F managers own RNAC?
6 of the 30 tracked 13F managers held RNAC shares at their latest filing, $11.0M in all. The largest: Cliff Asness's AQR Capital Management (356K shares, $3.7M), Izzy Englander's Millennium Management (310K shares, $3.2M), Two Sigma Investments (296K shares, $3.1M), Steve Cohen's Point72 Asset Management (44K shares, $455K), D. E. Shaw & Co. (29K shares, $299K), Renaissance Technologies (20K shares, $212K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.